Active Infection & Immunity NIHR-supported project Lungs & Breathing
A phase 1, first-in-human safety and immunogenicity study of a Lassa fever vaccine, ChAdOx1 LassaJ, in healthy volunteers aged 18 55 years in the UK.
About this grant
This summary is based on the grant title only — the full abstract was not available.
No substantive source abstract was published for this research project funded by NIHR.
Researchers
Maheshi Ramasamy (Principal Investigator)
Related Research
Grants with similar aims, by meaning.
A phase 1, first-in-human safety and immunogenicity study of a Marburg virus vaccine, ChAdOx1 Marburg, in healthy volunteers aged 18 55 years in the UK
A phase 1 safety and immunogenicity study of a Crimean-Congo haemorrhagic fever virus vaccine, ChAdOx2 CCHF, in healthy adult volunteers in the UK
A phase I/II study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers
A single-blind, randomised, phase II study to determine safety and, immunogenicity of the Coronavirus Disease (COVID-19) vaccine ChAdOx1 in UK healthy children and adolescents (aged 6-17)
A Phase 2/3 study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers
Original classification
Life-saving VaccinesPlain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know